Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.
Escamilla-Gómez V, García Gutiérrez V, Alcalde-Mellado P, Astibia-Mahillo B, Chinea-Rodriguez A, López-Corral L, Acera-Gómez M, Torres Ochando MK, Borrero Borrego A, González Pinedo L, Zudaire Ripa T, González Vicent M, Benzaquén A, Izquierdo Garcia I, Asensi Cantó P, Montoro J, Martín-Domínguez FM, Orti G, Valcárcel D, Benitez-Carabante MI, Diaz-de-Heredia C, Cañamero E, Ferrá C, García-Cadenas I, Redondo S, Sisinni L, Perez-Martínez A, Mussetti A, Garcia-Mañó L, Palomo-Moraleda MDP, González-Sierra PA, Jurado M, Perez-Simon JA; GETH-TC. Escamilla-Gómez V, et al. Among authors: valcarcel d. Bone Marrow Transplant. 2024 Dec 11. doi: 10.1038/s41409-024-02483-0. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39663471
Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.
Martínez C, Solano C, Ferrá C, Sampol A, Valcárcel D, Pérez-Simón JA; Spanish Group for Stem Cell Transplantation (Grupo Español de Trasplante Hemopoyético y Terapia Celular). Martínez C, et al. Among authors: valcarcel d. Biol Blood Marrow Transplant. 2009 May;15(5):639-42. doi: 10.1016/j.bbmt.2009.01.014. Epub 2009 Mar 9. Biol Blood Marrow Transplant. 2009. PMID: 19361757 Free article. Clinical Trial.
GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT.
Parody R, Lopez-Corral L, Godino OL, Cadenas IG, Martinez AP, Vazquez L, Martino R, Martinez C, Solano C, Barba P, Valcarcel D, Caballero-Velazquez T, Marquez-Malaver FJ, Sierra J, Caballero D, Perez-Simón JA. Parody R, et al. Among authors: valcarcel d. Bone Marrow Transplant. 2015 Jan;50(1):121-6. doi: 10.1038/bmt.2014.220. Epub 2014 Oct 13. Bone Marrow Transplant. 2015. PMID: 25310306 Clinical Trial.
Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.
Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA. Kharfan-Dabaja MA, et al. Among authors: valcarcel d. Bone Marrow Transplant. 2017 Mar;52(3):438-444. doi: 10.1038/bmt.2016.269. Epub 2016 Nov 7. Bone Marrow Transplant. 2017. PMID: 27819684 Free article.
Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation.
Ortí G, García-Cadenas I, López-Corral L, Pérez A, Jimenez MJ, Sánchez-Ortega I, Alonso L, Sisinni L, Fox L, Villacampa G, Badell I, de Heredia CD, Parody R, Ferrà C, Solano C, Caballero D, Martino R, Querol S, Valcárcel D. Ortí G, et al. Among authors: valcarcel d. Bone Marrow Transplant. 2019 Jul;54(7):1133-1137. doi: 10.1038/s41409-018-0422-z. Epub 2018 Dec 13. Bone Marrow Transplant. 2019. PMID: 30546069 No abstract available.
Author Correction: Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation.
Ortí G, García-Cadenas I, López-Corral L, Pérez A, Jimenez MJ, Sánchez-Ortega I, Alonso L, Sisinni L, Fox L, Villacampa G, Badell I, de Heredia CD, Parody R, Ferrà C, Solano C, Caballero D, Martino R, Querol S, Valcárcel D. Ortí G, et al. Among authors: valcarcel d. Bone Marrow Transplant. 2019 Jul;54(7):1176. doi: 10.1038/s41409-019-0471-y. Bone Marrow Transplant. 2019. PMID: 30733543
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
Cabrero M, López-Corral L, Jarque I, de la Cruz-Vicente F, Pérez-López E, Valcárcel D, Sanz J, Espigado I, Ortí G, Martín-Calvo C, de la Serna J, Caballero D; Grupo Español de Trasplante Hematopoyético (GETH) and Grupo Español de Linfomas y Trasplante Autólogo (GELTAMO). Cabrero M, et al. Among authors: valcarcel d. Bone Marrow Transplant. 2024 Mar;59(3):359-365. doi: 10.1038/s41409-023-02171-5. Epub 2024 Jan 2. Bone Marrow Transplant. 2024. PMID: 38167647 Clinical Trial.
Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies.
Fox ML, García-Cadenas I, Navarro V, Martínez AP, Kara M, Bazán IS, Ferra Coll C, Bailén R, Bento L, Parody R, Esquirol A, Ortí G, Mussetti A, Salamero O, Martino R, González AP, Barba P, Kwon M, Solano C, Bosch F, Valcárcel D; Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). Fox ML, et al. Among authors: valcarcel d. Bone Marrow Transplant. 2024 Oct;59(10):1369-1375. doi: 10.1038/s41409-024-02322-2. Epub 2024 Jun 24. Bone Marrow Transplant. 2024. PMID: 38914883
175 results